title: Efalizumab in the treatment of psoriasis.
abstract: The humanized antibody efalizumab is currently the only T-cell directed biologic approved for the treatment of moderate-to-severe psoriasis by both American and European authorities. Binding to and blocking the function of the adhesion molecule leukocyte function associated antigen 1 (LFA-1), it is believed to interfere with T-cell activation in the lymph node, migration through the circulation into the skin, and re-activation in-loco, all of these representing central steps in the pathogenesis of psoriasis. A comprehensive clinical development program provided large and consistent evidence that efalizumab induces a major clinical benefit in psoriasis. Efalizumab rapidly and substantially improves psoriatic skin symptoms and leads to profound gain in quality of life. It allows safe and effective long-term control of psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to severe plaque-type psoriasis.
authors.affiliation: Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
authors.forename: Wolf-Henning
authors.initials: WH
authors.lastname: Boehncke
references.citation: J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6
references.pmid: 11756941
references.citation: JAMA. 2003 Dec 17;290(23):3073-80
references.pmid: 14679270
references.citation: Arch Dermatol. 2005 Jan;141(1):82-4
references.pmid: 15655149
references.citation: J Rheumatol. 2006 Jul;33(7):1447-51
references.pmid: 16724367
references.citation: J Invest Dermatol. 1978 Nov;71(5):340-3
references.pmid: 309493
references.citation: J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S182-8
references.pmid: 16488340
references.citation: Br J Dermatol. 2004 Aug;151 Suppl 69:3-17
references.pmid: 15265063
references.citation: Arch Dermatol. 2005 Jan;141(1):31-8
references.pmid: 15655139
references.citation: J Rheumatol. 2006 Jul;33(7):1442-6
references.pmid: 16724368
references.citation: Br J Dermatol. 2005 Sep;153(3):486-97
references.pmid: 16120132
references.citation: J Am Acad Dermatol. 1999 Oct;41(4):581-3
references.pmid: 10495380
references.citation: J Clin Pharmacol. 2005 Mar;45(3):286-98
references.pmid: 15703364
references.citation: Am J Pathol. 1999 Jul;155(1):145-58
references.pmid: 10393847
references.citation: Nat Immunol. 2004 Apr;5(4):363-72
references.pmid: 15052266
references.citation: N Engl J Med. 2003 Nov 20;349(21):2004-13
references.pmid: 14627785
references.citation: J Am Acad Dermatol. 2001 Nov;45(5):665-74
references.pmid: 11606914
references.citation: BMJ. 1990 Apr 7;300(6729):908
references.pmid: 2337714
references.citation: J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98
references.pmid: 16922950
references.citation: J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S154-63
references.pmid: 16488337
references.citation: N Engl J Med. 2005 May 5;352(18):1899-912
references.pmid: 15872205
references.citation: J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33
references.pmid: 15761420
references.citation: J Am Acad Dermatol. 2000 Mar;42(3):428-35
references.pmid: 10688712
references.citation: J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-7
references.pmid: 10459113
references.citation: J Immunol. 1985 May;134(5):3272-80
references.pmid: 2580022
references.citation: Arch Dermatol. 1990 Nov;126(11):1523
references.pmid: 2241215
references.citation: J Dtsch Dermatol Ges. 2006 Nov;4 Suppl 2:S1-126
references.pmid: 17187649
references.citation: Arch Dermatol. 2002 May;138(5):591-600
references.pmid: 12020219
references.citation: J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
references.pmid: 15083780
references.citation: J Immunol. 1996 Dec 1;157(11):4986-95
references.pmid: 8943405